We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01638546
Recruitment Status : Completed
First Posted : July 11, 2012
Last Update Posted : February 10, 2017
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Primary Completion Date : January 2017
  Study Completion Date : January 2017

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 February 27, 2018